The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer

Table 6 Univariate and multivariate analyses of prognostic factors for relapse-free survival according to the period of adjuvant chemotherapy

Factors (RFS)	Univariate analysis	Multivariate analysis
Factors (RFS)	p value	p value	Hazard ratio	95 % CI
Age
<65 vs. >65 years	.667	.485	1.110	0.829–1.485
Sex
Male vs. female	.831	.820	0.965	0.708–1.315
Depth of tumor invasion
t1, 2 vs. t3, 4	<.001	.005	2.382	1.304–4.353
Lymph node metastasis
n0, 1 vs. n2, 3	<.001	.016	2.128	1.154–3.927
Histological type (WHO)
Undifferentiated vs. differentiated	.904	.015	0.516	0.303–0.881
Lauren classification
Diffuse vs. intestinal	.050	.012	1.936	1.158–3.237
Stage
II vs. III	<.001	.115	1.706	0.877–3.319
Period of adjuvant chemotherapy
< 6 months	<.001	.049	1.481	1.001–2.192
6~12 months	.037	.487	1.171	0.750–1.829
12~24 months	.172	.022	0.593	0.379–0.926
>24 months	.074	.018	0.438	0.221–0.870

ISSN: 1477-7819